Sign In
Last checked at 
10 Sep 2018 07:00
OptiBiotix Health plc
("OptiBiotix")
Director Appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):
Current Appointments | Appointments in the last 5 years |
ACCSYS Technologies Plc | Croda Enterprises Limited |
Applied Graphene Materials Plc | Croda Europe Limited |
Turner & Townsend Limited | Croda International Plc |
| Croda Investments Limited |
| Croda Investments No 2 Limited |
| Croda JDH Limited |
| Croda Overseas Holdings Limited |
| Croda Polymers International Limited |
| Croda World Traders Limited |
| Eminate Limited |
| Produce Investments Limited |
For further information, please contact:
OptiBiotix Health plc | www.optibiotix.com | |
Stephen O'Hara, Chief Executive | Contact via Walbrook below | |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico Lazzaretti | ||
finnCap (Broker) |
Tel: 020 7220 0500 | |
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance) | ||
Camille Gochez (Corporate Broking) | ||
Walbrook PR Ltd | Tel: 020 7933 8780 or optibiotix@walbrookpr.com | |
Anna Dunphy | Mob: 07876 741 001 | |
Lianne Cawthorne | Mob: 07584 391 303 | |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Follow the stocks
